MEDIA RELEASE
15 December 2021

CanPharma to assist patient access to medicinal cannabis and reimbursement via GWQ health insurance agreement

Health House International Ltd (**ASX:HHI**) (**Health House** or **the Company** or together with the entities it controls **the Group**), announced today its wholly-owned subsidiary CanPharma GmbH ("CanPharma") has entered into an agreement with GWQ Service Plus AG ("GWQ"), a company that represents 47 German public health insurance funds.

CanPharma will be a preferred supplier of a selection of its own-branded flowers and extracts to more than 30 of the 47 insurance companies that are shareholders in GWQ.

Doctors will be able to prescribe selected CanPharma medicinal cannabis products from their shortlist of suppliers to new patients who are insured by GWQ affiliated insurance funds in order for the patients to be eligible for reimbursement.

CanPharma is one of the few German cannabis companies qualified for the scheme due to its GMP manufacturing licence and is one of only a handful of cannabis company members of the GWQ scheme.

CanPharma Chief Executive Officer, and Health House Executive Director, Dr Henrik Sprengel, said "Following our decision to register a selection of our extracts and strains in the contract we hope it will increase the acceptance of cannabis as medicine by German prescribers particularly once they see that the insurance companies endorse a

Health House International Limited ACN 149 197 651 (ASX:HHI)
+61 8 6558 0886 - Level 3, 101 St Georges Tce Perth WA 6000
admin@healthhouse.com.au - www.healthhouse.com.au

1

reimbursement scheme. In general, over one third of applications for reimbursement of medicinal cannabis are rejected and we hope that this new approach increases both the number of new prescriptions as well as the percentage reimbursed".

In Germany public Healthcare is provided through a Statutory Health Insurance (SHI) that covers 90% of the population: GWQ is a service provider for public insurance funds that cover approximately 10% of the SHI market.

"We are delighted to see that CanPharma´s manufacturing licence and its pharma-focussed approach to the market are bearing fruit: this contract will serve as a solid reference in our ongoing discussions with other insurance companies throughout Germany ", said David Attwood, Chief Executive Officer, Health House.

For full details on the Agreement please refer to the ASX Announcement – 15 December 2021

About Health House

Health House International and the entities it controls **(the Group)** is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences. The Group supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe. The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.

For more information, please visit www.healthhouse.com.au

Address	**Contact**
Level 3	**David Attwood**
101 St Georges Tce	Chief Executive Officer
Perth WA 6000	David.attwood@healthhouse.com.au
AUSTRALIA	
Tel: +61 8 6558 0886	**Tim Slate**
Fax: +61 8 6316 3337	Company Secretary
E: admin@healthhouse.com.au	tim.slate@healthhouse.com.au
W: www.healthhouse.com.au	

Health House International Limited ACN 149 197 651 (ASX:HHI)
+61 8 6558 0886 - Level 3, 101 St Georges Tce Perth WA 6000
admin@healthhouse.com.au - www.healthhouse.com.au

2